Clare Arnott

About Associate Professor Clare Arnott

Program Director, Heart Failure Program, Cardiovascular

  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

Associate Professor Clare Arnott is Director of the Cardiovascular Program at The George Institute for Global Health and Associate Professor in Medicine at UNSW Sydney. 

A/Prof Arnott’s research focuses on women’s heart disease, heart failure, cardiovascular imaging, and cardio-kidney-metabolic (CKM) disease. Her work has significantly influenced national health policy and clinical management. 

As an experienced clinical trialist and the recipient of $28 million in research funding, A/Prof Arnott is an expert in investigating novel cardiometabolic treatments and pregnancy-related cardiovascular diseases including pre-eclampsia and pulmonary hypertension. 

She is also the Pagent Director of Heart Lung Clinical Research at St Vincent's Hospital, Sydney, Director and Founder of the Women’s Heart Clinic at Royal Prince Alfred Hospital, and Senior Staff Specialist Cardiologist at St Vincent’s Hospital and Royal Prince Alfred Hospital, Sydney.

A/Prof Arnott is a Fellow of the Cardiac Society of Australia and New Zealand and the European Society of Cardiology, and member of the ANZACT Steering Committee, as well as serving on the editorial board of Heart, Lung and Circulation

 

SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials

Clinical Journal of the American Society of Nephrology Date published:

Higher versus lower mean arterial blood pressure after cardiac arrest and resuscitation ( MAP - CARE ): A protocol for a randomized clinical trial

Acta Anaesthesiologica Scandinavica Date published:

Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD

Kidney International Reports Date published:

Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial

Diabetes, Obesity and Metabolism Date published:

Related Readings